Company: RPTX
Filing Date: 2025-11-17
Form Type: DEFA14A
Source: 0001193125-25-284040
Chunk: 127

Company: Repare Therapeutics Inc.
Filing Date: 2025-11-17
Form: DEFA14A
Chunk 127
---
 any notice or                                                                                                                                     
 obtain any permit as a condition to the lawful consummation of the transactions contemplated by this Agreement or otherwise obtain any governmental approvals, other than (i) the filing with the SEC of such reports under the US Exchange Act as  
 may be required in connection with the Agreement and the Contemplated Transactions and (ii) filings required to be made following the Effective Time under applicable Securities Laws. Except for such notices as have been given and such consents 
 as have been obtained, there is no requirement under any Material Contract to give any notice to, or to obtain the consent or approval of, any Party to such Material Contract, relating to, in connection with or as a result of the execution and 
 delivery of this Agreement or the consummation of the transactions contemplated this Agreement.                                                                                                                                                     |

| 37. | Intellectual Property Matters |

| (a) | To the knowledge of the Company, neither the Company nor or its Subsidiary has received any written notice or                                                         
 claim challenging the Company or its Subsidiary with respect to the validity of, use of or ownership of the Intellectual Property used or owned by it, as applicable. |

| (b) | The operation or conduct of the business of the Company and its Subsidiary, and the use of any of the                                                                                                                                                    
 Intellectual Property used in connection therewith, does not infringe upon the Intellectual Property rights of any person. No claims have been asserted or are, to the knowledge of the Company, threatened by any person alleging that the operation or 
 conduct of the business of the Company and its Subsidiary infringes upon any of its Intellectual Property rights. Intellectual Property owned or used by Company and its Subsidiary is valid and enforceable, except as would not be expected to have a  
 Material Adverse Change on the Company.                                                                                                                                                                                                                  |

| (c) | Except as set forth in Schedule 37(c) of the Disclosure Letter, there are no other Contracts between the                                                                                                                                               
 Company (or any predecessor or any Affiliate thereof), on the one hand, and any other person (or any predecessor or Affiliate thereof), on the other hand, that requires the payment by the Company of any royalty payment, milestone payment or other 
 contingent payment of any kind in connection with the discovery, research, development, manufacture, use, sale or other exploitation of any Company Assets.                                                                                            |

| 38. | Data Security and Privacy Requirements |

| (a) | The Company and its Subsidiary